Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin-facilitated Treatment for Chronic Pain
NCT05068791Phase 1Recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Nov 2023
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in fibromyalgia (FM) comparing Psilocybin with Active Placebo (2 arms). Primary endpoint: Change in daily self-reported pain severity at 13 weeks. Started Nov 2023; status: recruiting.
02
Drugs
psilocybin
03
Conditions
fibromyalgia (FM)
Beyond the preview
Go deeper on NCT05068791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05068791.